Table 2 Raw incidence of gout at timepoints 3, 5, 10, 12 and 15 years of follow-up in the cohort in combined cohort, males and females
Serum urate (mg/dL) | N | 3 Years | 5 Years | 10 Years | 12 Years | 15 Years | |
|---|---|---|---|---|---|---|---|
All | < 4.00 | 2490 | 0.08% | 0.20% | 0.46% | 0.52% | 0.59% |
4.00–4.49 | 1896 | 0.27% | 0.32% | 0.71% | 0.94% | 1.28% | |
4.50–4.99 | 2383 | 0.13% | 0.30% | 0.65% | 0.75% | 0.86% | |
5.00–5.49 | 2535 | 0.16% | 0.24% | 0.83% | 0.94% | 0.94% | |
5.50–5.99 | 2363 | 0.13% | 0.34% | 0.93% | 1.27% | 1.52% | |
6.00–6.49 | 2192 | 0.28% | 0.51% | 1.33% | 1.73% | 2.91% | |
6.50–6.99 | 1810 | 0.22% | 0.45% | 1.96% | 2.81% | 3.20% | |
≥7.00 | 3220 | 1.44% | 3.41% | 7.95% | 10.44% | 12.22% | |
Males | < 4.00 | 202 | 0.53% | 1.61% | 2.25% | 2.25% | 2.25% |
4.00–4.49 | 291 | 0.00% | 0.35% | 1.09% | 1.74% | 2.41% | |
4.50–4.99 | 594 | 0.51% | 0.51% | 1.06% | 1.06% | 1.41% | |
5.00–5.49 | 968 | 1.41% | 1.41% | 0.57% | 0.80% | 0.80% | |
5.50–5.99 | 1226 | 0.17% | 0.42% | 0.93% | 1.31% | 1.71% | |
6.00–6.49 | 1365 | 0.37% | 0.74% | 1.44% | 1.80% | 3.35% | |
6.50–6.99 | 1260 | 0.32% | 0.56% | 1.97% | 3.03% | 3.50% | |
≥7.00 | 2374 | 1.66% | 3.80% | 7.87% | 9.84% | 11.38% | |
Females | < 4.00 | 2288 | 0.04% | 0.09% | 0.32% | 0.38% | 0.45% |
4.00–4.49 | 1605 | 0.25% | 0.32% | 0.64% | 0.78% | 1.06% | |
4.50–4.99 | 1789 | 2.31% | 0.23% | 0.52% | 0.66% | 0.66% | |
5.00–5.49 | 1567 | 0.26% | 0.39% | 0.99% | 0.99% | 0.99% | |
5.50–5.99 | 1137 | 0.09% | 0.27% | 0.92% | 1.21% | 1.21% | |
6.00–6.49 | 827 | 0.12% | 0.12% | 1.15% | 1.72% | 1.72% | |
6.50–6.99 | 550 | 2.44% | 0.19% | 1.97% | 1.97% | 1.97% | |
≥7.00 | 846 | 0.84% | 2.30% | 8.19% | 13.06% | 16.45% |